資料下載
Data download
熱門搜索：
Fitzgerald Industries International代理
Envirologix 轉基因快速檢測試紙
Epitomics現貨抗體目錄
ABgene代理30
EVE™ Slide（EVE細胞計數板）
Cayman Chemical 特約代理
法國ID-VET
Sinobio公司產品介紹
美國Sutter 玻璃毛坯 BF100-50-10
genview
D12079BWestern Diet(高純度飼料)
polysciences公司中國總代理
TEAA Solution（貨號：553303;SP5890）
LSPN-50ABMI公司LYSOSTAPHIN中國總代理
Abcam代理
天然小鼠補體C1q蛋白
發布時間：2025/12/19
點擊次數：3
荷蘭ipatherapeutics是一家專注于生物治療領域創新發展的生物科技企業，核心聚焦抗體發現與AI技術融合應用，憑借生物技術平臺和人工智能算法，為生物醫藥領域提供高效、精準的抗體解決方案，助力推動生物治療技術的突破與升級。其核心優勢在于將AI技術深度賦能抗體研發全流程，有效提升研發效率與精準度，在高特異性、高親和力抗體開發領域具備顯著行業競爭力。
公司構建了多元化的核心產品線，覆蓋診斷、藥物研發、疫苗研發等多個關鍵領域。其中，B細胞選擇®兔子單克隆抗體是其標志性產品之一，該產品融合兔子免疫系統的高特異性與高親和力優勢，結合公司的Function-First B細胞選擇工作流程，可早期識別優質診斷抗體，為精準醫療提供核心支撐。針對小型處理蛋白質和復雜二級結構靶點，公司開發的轉基因動物模型能生成序列多樣性豐富、生物相關性強的候選物，大幅拓寬了抗體應用邊界。此外，多通膜蛋白靶向抗體通過BLI平臺特異性測試，結合抗體庫親和力排名、表位繪圖等技術優化，可精準靶向GPCRs、離子通道等難以成藥的膜蛋白靶點，通過雜交瘤測序、人源化等技術加工，為客戶提供定制化高質量抗體產品。
在研發與市場布局上，ipatherapeutics持續加大研發投入，強化技術壁壘，其AI驅動的LENSai™平臺相關應用經基準測試驗證，可僅通過序列數據實現與X射線晶體學相當的表位映射準確性，有效解決行業內抗體研發失敗率高、周期長、成本高的痛點。公司客戶群體覆蓋生物技術公司、制藥企業、科研機構及學術界，通過定制化解決方案滿足不同客戶的研發與應用需求。同時，公司積極踐行社會責任，致力于通過創新生物治療產品改善健康，推動可持續發展，減少環境影響，并支持教育與科研項目，培育生物治療領域專業人才。目前，公司通過經銷商網絡拓展市場覆蓋，其中上海起發作為其中國區域經銷商，為國內客戶提供全面的產品與服務支持。
關鍵詞：ipatherapeutics，ipatherapeutics上海代理，ipatherapeutics中國代理，ipatherapeutics北京代理，ipatherapeutics江蘇代理， ipatherapeutics廣東代理,N002-100ML, N001-0.5mg, N001-0.1mg, R001-100ML, L101-0.025mg immunoprecise u-proteinexpress，ipatherapeutics、荷蘭ipatherapeutics生物公司、ipatherapeutics抗體發現、AI驅動生物治療、ipatherapeutics單克隆抗體、B細胞選擇兔子單克隆抗體、轉基因動物模型、多通膜蛋白靶向抗體、ipatherapeutics AI研發平臺、LENSai™平臺、精準醫療抗體、GPCRs靶向抗體、離子通道抗體、生物治療創新企業、荷蘭生物科技公司、ipatherapeutics定制抗體、生物醫藥研發解決方案、ipatherapeutics合作伙伴、腫瘤治療抗體、ipatherapeutics中國經銷商
特別告知：為保證產品質量與良好性能，所以在購買相應產品的同時我司會收取一定量的運輸費用?。。”敬螆髢r有效時間為2025年12月19日---2026年12月20日。
（*此為部分產品價格,完整價格請下載文件)
貨號 | 品名 | 規格 | 價格 | 品牌 |
CC0006H | mouse anti-Salmonid Ig antibody | 100ug | 7761.6 | ipatherapeutics |
CC008PG | mouse anti rainbow trout IgG heavy chain antibody | 500µg | 6534 | ipatherapeutics |
CC0116F | mouse anti-Flavobacterium psychrophilum antibody | 100ug | 7761.6 | ipatherapeutics |
MQ1.201 | mouse anti-human Rpp20 antibody | 100ug | 7761.6 | ipatherapeutics |
MQ2.103 | mouse anti-human rhomboid-related protein 4 antibody | 100ug | 7761.6 | ipatherapeutics |
MQ5.101 | mouse anti-collagenase G antibody | 100ug | 6850.8 | ipatherapeutics |
MQ5.201 | mouse anti-collagenase antibody | 100ug | 6850.8 | ipatherapeutics |
MQ5.202 | mouse anti-collagenase antibody | 100ug | 6850.8 | ipatherapeutics |
MQ6.102 | mouse anti-enhanced blue fluorescent protein antibody | 100ug | 4197.6 | ipatherapeutics |
MQ6.104 | mouse anti-enhanced blue fluorescent protein antibody | 100ug | 3583.8 | ipatherapeutics |
MQ7.101 | mouse anti-Trypanosoma cruzi antibody | 100ug | 8375.4 | ipatherapeutics |
MQ7.102 | mouse anti-Trypanosoma cruzi antibody | 100ug | 8375.4 | ipatherapeutics |
MQ7.103 | mouse anti-Trypanosoma cruzi antibody | 100ug | 8375.4 | ipatherapeutics |
MQ10.101 | mouse anti-receptor-type tyrosine-protein phosphatase R isoforms antibody | 100ug | 6534 | ipatherapeutics |
MQ13.101 | mouse anti-citrullinated fibrinogen antibody | 100ug | 8771.4 | ipatherapeutics |
MQ13.102-100ug | mouse anti-citrullinated fibrinogen antibody | 100ug | 9385.2 | ipatherapeutics |
MQ13.102-1mg | mouse anti-citrullinated fibrinogen antibody | 1mg | 65577.6 | ipatherapeutics |
MQ13.104 | mouse anti-citrullinated fibrinogen antibody | 100ug | 8771.4 | ipatherapeutics |
MQ14.103 | mouse anti-chicken IgY antibody | 100ug | 3583.8 | ipatherapeutics |
MQ20.101 | mouse anti-VSV-G tag antibody | 100ug | 6534 | ipatherapeutics |
MQR1.101 | mouse anti-citrullinated fibrinogen antibody | 100ug | 12553.2 | ipatherapeutics |
MQR2.101-100ug | human anti-citrullinated fibrinogen antibody | 100ug | 12553.2 | ipatherapeutics |
MQR2.101-1mg | human anti-citrullinated fibrinogen antibody | 1mg | 93515.4 | ipatherapeutics |
MQR2.1201 | human anti-human bromodomain-containing protein 4 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1301 | human anti-human WD repeat-containing protein 5 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1401 | human anti-human bromodomain and PHD finger-containing protein 3 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1501 | human anti-human bromodomain-containing protein 1 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1601 | human anti-human protein arginine N-methyltransferase 3 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1701 | human anti-human TP53-binding protein 1 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1801 | human anti-human hepatoma-derived growth factor-related protein 2 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.1901 | human anti-human fragile X mental retardation syndrome-related protein 2 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2001 | human anti-human histone lysine demethylase PHF8 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2101 | human anti-human zinc finger CCCH-type with G patch domain-containing protein monoclonal antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2201 | human Anti-SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4 isoform B antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2301 | human anti-codanin-1 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2401 | human anti-dehydrogenase E1 and transketolase domain containing protein 1 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2701 | human anti-threonyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2901 | human anti-alanyl-tRNA synthetase (C1&C2) antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.2902 | human anti-alanyl-tRNA synthetase (C2) antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3001 | human anti-methionyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3201 | human anti-Four and a half LIM domains protein 1 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3301 | human anti-Nuclear body protein SP140 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3401 | human anti-tryptophanyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3601 | human anti-SprT-like N-terminal domain antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3701 | human anti-galactose-1-phosphate uridylyltransferase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3801 | human anti-histidyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.3901 | human anti-seryl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.4001 | human anti-lysyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.4101 | human anti-asparaginyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.4201 | human anti-arginyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.4301 | human anti-aspartyl-tRNA synthetase antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.4401 | human anti-Interleukin 8 antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.201 | human anti-apoptotic cleavage product of human U1-70K antibody | 100ug | 8375.4 | ipatherapeutics |
MQR2.201-BSA | human anti-apoptotic cleavage product of human U1-70K antibody | 100ug | 8375.4 | ipatherapeutics |
MQR1.602 | mouse anti-modified citrulline antibody | 100ug | 12553.2 | ipatherapeutics |
MQR2.601 | human anti-modified citrulline antibody | 100ug | 12553.2 | ipatherapeutics |
MQR2.602 | human anti-modified citrulline antibody | 100ug | 12553.2 | ipatherapeutics |
MQR2.701 | human anti-matrix metallopeptidase-14 antibody | 100ug | 6336 | ipatherapeutics |
MQR2.801 | human anti-resistin antibody | 100ug | 6336 | ipatherapeutics |
MQR1.901 | mouse anti-phosphoserine peptide antibody | 100ug | 6336 | ipatherapeutics |
MQR1.1001 | mouse anti-acetylated lysine peptide | 100ug | 6019.2 | ipatherapeutics |
MQR1.1101 | mouse anti-ubiquitin antibody | 100ug | 6019.2 | ipatherapeutics |
A001 | Alkaline Phosphatase, Placenta, Human, Secreted (Mannitol Buffer) | 250ug | 11226.6 | ipatherapeutics |
A002 | Alkaline Phosphatase, Placenta, Human, Secreted (Glycerol Buffer) | 250ug | 11226.6 | ipatherapeutics |
A004 | ACE-2-(TEV-Fc)C, human | 100ug | 9603 | ipatherapeutics |
A005 | ACE-2, human | 100ug | 10098 | ipatherapeutics |
A006-0.025mg | Wild type Alpha-1-Antitrypsin-(his)N | 0.025mg | 3069 | ipatherapeutics |
A006-0.1mg | Wild type Alpha-1-Antitrypsin-(his)N | 0.10mg | 8157.6 | ipatherapeutics |
A007-0.025mg | Alpha-1-antitrypsin-Pittsburgh-(his)N | 0.025mg | 3069 | ipatherapeutics |
A007-0.1mg | Alpha-1-antitrypsin-Pittsburgh-(his)N | 0.10mg | 8157.6 | ipatherapeutics |
A008-0.025mg | Alpha-1-antitrypsin-Portland-(his)N | 0.025mg | 3069 | ipatherapeutics |
A008-0.1mg | Alpha-1-antitrypsin-Portland-(his)N | 0.10mg | 8157.6 | ipatherapeutics |
B001 | Complement Factor B, Human | 100ug | 7662.6 | ipatherapeutics |
B002 | Complement Factor B, Human, Man5-Glcnac2 N-Linked Glycans | 100ug | 8157.6 | ipatherapeutics |
C001 | Complement C2, Human | 100ug | 8375.4 | ipatherapeutics |
C002 | CGREF1, Human | 100µg | 9603 | ipatherapeutics |
C003 | CD40-ECD, Human | 100ug | 9603 | ipatherapeutics |
C004 | CD40-ECD, Mus Musculus | 100ug | 9603 | ipatherapeutics |
C005 | CTLA4-Ecd, Human | 100ug | 9603 | ipatherapeutics |
C006 | CTLA4-Ecd, Mus Musculus | 100ug | 9603 | ipatherapeutics |
C007 | CD36 Extra Cellular Domain, Human | 100ug | 17641.8 | ipatherapeutics |
C008 | Complement C5A, Human | 100ug | 9603 | ipatherapeutics |
C009 | C1QR-(His)N, Human, Recombinant | 100ug | 11226.6 | ipatherapeutics |
C013 | Ca3, human | 100ug | 8058.6 | ipatherapeutics |
C014 | C3adesR, human | 100ug | 8058.6 | ipatherapeutics |
D001 | DPPA, E. Coli | 250ug | 12355.2 | ipatherapeutics |
D002 | Complement Factor D, Human | 100ug | 11226.6 | ipatherapeutics |
F001 | FSH, Danio Rerio | 100ug | 10711.8 | ipatherapeutics |
F002 | Fam3D, Human | 100ug | 10098 | ipatherapeutics |
G001 | Growth Hormone | 100ug | 11840.4 | ipatherapeutics |
G002 | Beta2-Glycoprotein I | 100µg | 8989.2 | ipatherapeutics |
G003 | Glycoprotein Ib alpha, Fully Sulfated Form, Human | 100ug | 8989.2 | ipatherapeutics |
G004 | Glycoprotein Ib alpha, Double Sulfated Form, Human | 100ug | 8989.2 | ipatherapeutics |
G005 | Glycoprotein Ib alpha, Single Sulfated Form, Human | 45ug | 11226.6 | ipatherapeutics |
G006 | Glycoprotein Ib alpha, Non-Sulfated Form, Human | 40ug | 11226.6 | ipatherapeutics |
G007 | Beta2-Glycoprotein I, Human, Without Purification Tag | 100µg | 10929.6 | ipatherapeutics |
G008 | Beta2-Glycoprotein I, Domain V, Human | 100µg | 9603 | ipatherapeutics |
G009 | Beta2-Glycoprotein I, Domain V, Human, Without Purification Tag | 100µg | 11226.6 | ipatherapeutics |
H001 | Herstatin, Human | 100ug | 8375.4 | ipatherapeutics |
I001 | Insulin Like Growth Factor 2, IGF2, Human | 100ug | 11226.6 | ipatherapeutics |
L101-0.025 mg | Lys-N | 25µg | 6534 | ipatherapeutics |
L101-0.1 mg | Lys-N | 0.1mg | 23463 | ipatherapeutics |
L101-0.5 mg | Lys-N | 0.5mg | 104940 | ipatherapeutics |
M001 | Mannose-Binding Protein C | 100ug | 11127.6 | ipatherapeutics |
M002 | MART1, Human | 100µg | 9999 | ipatherapeutics |
MQ16.201 | Human PAD2 | 2.5units | 13879.8 | ipatherapeutics |
MQ16.203 | Human PAD4 | 2.5units | 13879.8 | ipatherapeutics |
MQ17.101 | PAD Enzyme Assay | 1x96wellELISA | 13879.8 | ipatherapeutics |
MQ18.101 | Arthritis Antibody Mix | 50mg | 59142.6 | ipatherapeutics |
MQ21.101 | Fibrinogen, human, deiminated (huPAD2) | 100ug | 7761.6 | ipatherapeutics |
MQ21.101b | Fibrinogen, human deiminated, biotinylated (huPAD2) | 100ug | 7761.6 | ipatherapeutics |
MQ21.102 | Fibrinogen, human, deiminated (huPAD4) | 100ug | 7761.6 | ipatherapeutics |
MQ24.201-0.1mg | Glutathione S-transferase protein (GST) | 100µg | 2158.2 | ipatherapeutics |
當前位置：
